Phase 3 N=3,040 SWOG-9346, Hormone Therapy in Treating Men With Stage IV Prostate Cancer
Prostate Cancer
Primary: Overall Survival — 5.8; 5.1 years — p=0.15
Clinical Trial Search
Completed trials with posted results — search by concept, filter by the parameters that matter at the bedside.
Phase 2 N=36 Treating Patients With Metastatic Prostate Cancer Not Responding to Hormone and Chemotherapy
Adenocarcinoma of the Prostate · Recurrent Prostate Cancer · Stage IV Prostate Cancer
Primary: Proportion Responding to Treatment With of the Combination of Ixabepilone and Mitoxantrone Hydrochloride With Prednisone in Hormone Refractory Prostate Cancer Patients…
Phase 2 N=28 Systemic and Tumor-Directed Therapy for Oligometastatic Prostate Cancer
Newly Diagnosed Oligometastatic Prostate Cancer
Primary: Percentage of Participants With PSA<0.05ng/mL (Radical Prostatectomy) or PSA <Nadir+2ng/mL (Prostate Radiation) — 20 Participants
Phase 2 N=73 Docetaxel, Thalidomide, Prednisone, and Bevacizumab to Treat Metastatic Prostate Cancer
Prostatic Neoplasms
Primary: Number of Participants Who Had a Prostate-specific Antigen (PSA) Response — 52 Participants
Phase 2 N=74 Docetaxel and PROSTVAC for Metastatic Castration-Sensitive Prostate Cancer
Prostate Cancer · Prostate Neoplasms · Neoplasms, Prostatic
Primary: Antigen Spreading (i.e., a Broader Immune Response) With Greater Associated Response Score Compared to Docetaxel Alone After 19 Weeks — 4.31; 5.63; 4.00 Score on a scale
Phase 2 N=40 PS-341 Followed by Removal of Prostate for Those With Prostate Cancer
Prostate Neoplasms
Primary: The Purpose of the Present Study is to Assess the Safety of PS-341 as a Pretreatment in Patients Who Are to Undergo a Radical Prostatectomy. Poor Wound Healing and…
Phase 2 N=32 Sequential Vaccinations in Prostate Cancer Patients
Prostatic Neoplasms
Primary: Number of Participants With an Immune Response — 2; 4; 4; 3 Participants
Phase 2 N=27 Postoperative Radiation Therapy, Hormonal Therapy and Concurrent Docetaxel for High Risk Pathologic Prostate Cancer
Prostate Cancer
Primary: Percentage of Patients Who Can Safely Tolerate and Complete Adjuvant Hormonal Therapy, Radiation Therapy and Docetaxel After a Radical Prostatectomy — 26 percentage of…
Phase 2 N=8 Nivolumab in Biochemically Recurrent dMMR Prostate Cancer
Prostate Cancer · Recurrent Prostate Cancer
Primary: Percentage of Participants With PSA50 Response — 2 Participants
Phase 2 N=16 Neoadjuvant Weekly Ixabepilone for High Risk, Clinically Localized Prostate Cancer
Prostate Cancer
Primary: Prostate-Specific Antigen (PSA) Response — 14 participants
Phase 2 N=10 Ipilimumab in Combination With Androgen Suppression Therapy in Treating Patients With Metastatic Hormone-Resistant Prostate Cancer
Adenocarcinoma of the Prostate · Hormone-resistant Prostate Cancer · Recurrent Prostate Cancer
Primary: Percentage of Patients Who Achieve an Undetectable PSA (=< 0.2 ng/ml) — 0.0 percentage of patients
Phase 2 N=71 Study of MDX-010 in Patients With Metastatic Hormone-Refractory Prostate Cancer
Prostate Cancer · Neoplasm Metastasis
Primary: Number of Participants With Serious AEs (SAEs), Adverse Events (AEs) Leading to Discontinuation, and Immune-related AEs - Treated Participants — 3; 2; 9; 2 participants
Phase 2 N=80 Radiation Therapy, Androgen Suppression, and Docetaxel in Treating Patients With High-Risk Prostate Cancer Who Have Undergone Radical Prostatectomy
Prostate Cancer
Primary: Number of Participants Free From Progression at 3 Years — 54 participants
Phase 2 N=129 Radiation Therapy in Treating Patients With Stage II or Stage III Prostate Cancer
Prostate Cancer
Primary: Percentage of Participants With Late Grade 3-5 Genitourinary (GU) and Gastrointestinal (GI) Adverse Events (AE) at 18 Months — 2.56 percentage of participants — p=<0.0001
Phase 2 N=27 Chemotherapy, Hormone Therapy, and Radiation Therapy in Treating Patients With Locally Advanced Prostate Cancer
Prostate Cancer
Primary: Toxicity — 2; 0 Events
Phase 2 N=9 A Phase 2 Trial of Bevacizumab, Lenalidomide, Docetaxel, and Prednisone (ART-P) for Treatment of Metastatic Castrate-Resistant Prostate Cancer
Metastatic Prostate Cancer
Primary: Recommended Phase 2 Dose (RP2D) — 25 mg
N/A N=77 Docetaxel, Androgen Deprivation and Proton Therapy for High Risk Prostate Cancer
Prostate Cancer
Primary: Acute Grade 3 or Higher Treatment-related Toxicity Rate. — 1; 3 participants — p=<0.0001
N/A N=22 PRAGMA (Prostate Radio Ablation Guided by Magnetic Resonance Imaging Acquisition) in Metastatic Prostate Cancer
Metastatic Prostate Cancer
Primary: Change in Number of Subjects With Adverse Events Will be Collected — 22; 18; 17 Participants
Phase 2 N=124 Ixabepilone in Treating Patients With Metastatic Prostate Cancer
Adenocarcinoma of the Prostate · Recurrent Prostate Cancer · Stage IV Prostate Cancer
Primary: Proportion of Patients With PSA Response — 0.33; 0.24; 0.18 Proportion of participants
Phase 2 N=26 A Study of Definitive Therapy to Treat Prostate Cancer After Prostatectomy
Prostate Cancer
Primary: Efficacy as Assessed by 3-year Prostate-specific Antigen Progression-free Survival Rate — 22; 3 Participants
Phase 2 N=45 Radiation and Androgen Ablation for Prostate Cancer
Adenocarcinoma of the Prostate
Primary: Biochemical Failure Free-rate (BFFR) Associated With the Combined Hypofractionated Dose Regimen and Androgen Deprivation Therapy (ADT). — 0 progression events
Phase 3 N=840 Radiation Therapy With or Without Bicalutamide for Recurrent pT3N0 Prostate Cancer After Radical Prostatectomy
Prostate Cancer
Primary: Overall Survival (12-year Rates Reported) — 71.3; 76.3 percentage of participants — p=0.020
Phase 3 N=1,532 Radiation Therapy in Treating Patients With Stage II Prostate Cancer
Prostate Cancer
Primary: Overall Survival — 88.5; 88.1 percentage of participants — p=0.98
Phase 3 N=1,050 Docetaxel and Prednisone With or Without Bevacizumab in Treating Patients With Prostate Cancer That Did Not Respond to Hormone Therapy
Adenocarcinoma of the Prostate · Hormone-resistant Prostate Cancer · Recurrent Prostate Cancer
Primary: Overall Survival — 21.5; 22.6 months — p=0.181
Phase 2 N=112 Hormone Therapy and Ipilimumab in Treating Patients With Advanced Prostate Cancer
Prostate Adenocarcinoma · Prostate Carcinoma · Recurrent Prostate Carcinoma
Primary: Number of Participants Progression-free at 18 Months — 0 participants
Phase 2 N=41 Docetaxel, Bevacizumab and Androgen Deprivation Therapy After Definitive Local Therapy for Prostate Cancer
Prostate Cancer
Primary: Prostate-Specific Antigen (PSA) Progression at 1 Year After Completing Androgen Deprivation Therapy (ADT) — 98 percentage of participants with data
Phase 2 N=17 A Phase II Study of Cabozantinib (XL184) Therapy in Castrate Resistant Prostate Cancer (CRPC) With Visceral Metastases
Prostate Cancer
Primary: Clinical Benefit Rate From Cabozantinib (XL184) — 10 Participants
Phase 3 N=109 Expanded Access to Diagnostic Imaging for Staging of Recurrent Prostate Cancer
Metastatic Prostate Cancer
Primary: Evidence of Metastatic Prostate Cancer — 0; 36; 0; 10 Participants
Phase 2 N=36 AMG 386 and Abiraterone for Advanced Prostate Cancer
Prostatic Neoplasms · Prostate Cancer · Neoplasm, Prostate
Primary: Progression Free Survival (PFS) — 2.8; 9.0; 11.5; 10.1 Months — p=0.44
Phase 3 N=1,038 S0421, Docetaxel and Prednisone With or Without Atrasentan in Treating Patients With Stage IV Prostate Cancer and Bone Metastases That Did Not Respond to Previous Hormone Therapy
Metastatic Cancer · Prostate Cancer
Primary: Compare Survival Between a Control or Standard Therapy Arm of Docetaxel + Placebo + Prednisone With Docetaxel + Atrasentan + Prednisone in Patients With Hormone…